Barclays Maintains an 'Overweight' on Mylan (MYL); EpiPen: Overcoming a Wall of Worry
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Price: $15.86 --0%
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Mylan (NASDAQ: MYL) price target of $26.00.
Analyst Douglas D. Tsao, says, "We believe recent investor concern regarding generic threats to MYL's EpiPen franchise is unwarranted given both the legal and, more importantly, regulatory issues. EpiPen has emerged as an important driver for MYL based recent reacceleration for the franchise through conversion to "2-Pak" and, more importantly, increased awareness through DTC advertising. We expect EpiPen to reach $530M in sales in 2012, up 33% from '11."
Tsao concluded by saying, "...With just 7% market penetration of epinephrine injectors, we believe EpiPen remains one of MYL's best revenue growth opportunities."
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $22.21 yesterday.
Analyst Douglas D. Tsao, says, "We believe recent investor concern regarding generic threats to MYL's EpiPen franchise is unwarranted given both the legal and, more importantly, regulatory issues. EpiPen has emerged as an important driver for MYL based recent reacceleration for the franchise through conversion to "2-Pak" and, more importantly, increased awareness through DTC advertising. We expect EpiPen to reach $530M in sales in 2012, up 33% from '11."
Tsao concluded by saying, "...With just 7% market penetration of epinephrine injectors, we believe EpiPen remains one of MYL's best revenue growth opportunities."
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $22.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- UBS Reiterates Buy Rating on HF Sinclair (DINO)
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
